Viral Pneumonia Treatment & Management
- Author: Zab Mosenifar, MD; Chief Editor: Zab Mosenifar, MD more...
Approach Considerations
All viral pneumonia patients must receive supportive care with oxygen, rest, antipyretics, analgesics, nutrition, and close observation. See Table 2 below.
Table 2. Treatment and Prevention of Common Causes of Viral Pneumonia (Open Table in a new window)
| Virus | Treatment | Prevention |
| Influenza virus | Amantadine Rimantadine | Influenza vaccine Chemoprophylaxis with: Amantadine Rimantadine Zanamivir Oseltamivir |
| Respiratory syncytial virus | Ribavirin | RSV immunoglobulin Palivizumab |
| Parainfluenza virus | Ribavirin | |
| Herpes simplex virus | Acyclovir | |
| Varicella-zoster virus | Acyclovir | Varicella-zoster immunoglobulin |
| Adenovirus | Ribavirin | |
| Measles virus | Ribavirin | Intravenous immunoglobulin |
| Cytomegalovirus | Ganciclovir Foscarnet | Intravenous immunoglobulin |
Supportive Care
Oxygen should be administered to patients with hypoxemia or shortness of breath. Emergency medical personnel should administer oxygen if the patient is dyspneic. Some prehospital providers can deliver aerosol treatments with beta-agonists, which may improve the patient's breathing. Patients with respiratory failure require endotracheal intubation and ventilator support.
Isotonic sodium chloride solution should be administered to patients who are in shock and have no component of heart failure.
Acute care may involve use of the following:
- Oxygen, if the patient is dyspneic
- Beta-agonists, if bronchospasm is present
- Fluids, if dehydration is present
- Acyclovir, if varicella or herpes pneumonia is suspected
- Respiratory isolation
- Antibiotics, if infiltrate is seen on the chest radiograph
- Mechanical ventilation if respiratory failure is present or impending
Influenza Pneumonia
Antiviral therapy is available for the treatment of influenza virus infection. The treatment of uncomplicated influenza is supportive in nature, consisting of rest and administration of antipyretics and analgesics. See Table 3 below.
Table 3. Characteristics of Anti-Influenza Drugs (Open Table in a new window)
| Amantadine (Symmetrel) | Rimantadine (Flumadine) | Zanamivir (Relenza) | Oseltamivir (Tamiflu) | |
| Mechanism of action | M2 ion channel blockade inhibits HA* cleavage beta block RNA encoding, which reduces early viral replication. | Viral NA† inhibition prevents sialic acid cleavage from HA beta virus gets trapped inside cells, and epithelial spread is blocked. | ||
| Spectrum | Influenza A only | Influenza A only | Influenza A and B | Influenza A and B |
| Oral bioavailability | Good | Good | Poor | Good |
| Protein binding, % | 67 | 40 | None | Minimal |
| Half-life, h | 12-18 | 24-36 | 2.5-5 | 1-3 |
| Excretion | Renal (not removed by hemodialysis) | Renal and gastrointestinal | Renal | |
| Drug interaction | Synergistic CNS toxicity with antihistamines, anticholinergics, CNS stimulants | Beta Plasma level: ASA§, acetaminophen | None | None |
| Renal clearance | TMP-SMZ¶, triamterene, hydrochlorothiazide, quinine sulfate, quinidine | Cimetidine | None | None |
| * HA - Hemagglutinin † NA - Neuraminidase § ASA - Acetylsalicylic acid ¶ TMP-SMZ - Trimethoprim and sulfamethoxazole | ||||
Amantadine hydrochloride and rimantadine hydrochloride are approved for the prevention and treatment of influenza A virus infection; they are not active against influenza B virus infection. Both drugs are absorbed well orally, block the viral M2 protein ion channel, and inhibit the uncoating of the virus. Rimantadine is a synthetic analog of amantadine and has comparable therapeutic efficacy.
Treatment with amantadine or rimantadine, given within 48 hours of the onset of symptoms, decreases the duration of fever and other symptoms by approximately 1 day in adults with uncomplicated disease. Their efficacy in patients with influenza viral pneumonia or severe influenza is unknown, but most clinicians are comfortable trying these agents in that setting, if the virus is susceptible.
Treatment with these compounds has been associated with the emergence of viral resistance; the clinical significance of this is not known. Many of the current strains are not susceptible to amantadine/rimantadine (including H1N1 influenza virus), so empiric use of these agents as the only drug is not recommended.
Oseltamivir, zanamivir, and peramivir block the neuraminidase surface protein on both influenza A and influenza B viruses.[68, 69, 70, 71, 72, 73]
These drugs trap the virus inside the infected respiratory epithelial cells and prevent spread to other cells. They are active against both influenza A and influenza B viruses. These newer drugs have a different safety profile and lower potential for inducing resistance, but they are much more expensive.
The results of zanamivir studies have confirmed its efficacy only if therapy is started within 24-48 hours of symptom onset in febrile patients. Most studies have reported a similar window of opportunity for oseltamivir. Like the older agents, they reduce the course of influenza by approximately 1 day. Oseltamivir (Tamiflu) resistance emerged in the United States during the 2008-2009 influenza season.
For severe influenza pneumonia, antiviral medication should be given, even after the 48-hour window.
In a double-blind, randomized controlled trial, one inhalation of laninamivir octanoate was shown as effective for the treatment of seasonal influenza in adults. Effectiveness was also shown for the oseltamivir-resistant virus.[74]
H1N1 influenza
In the 2009-2010 H1N1 influenza epidemic, the US Centers for Disease Control and Prevention (CDC) recommended oseltamivir or zanamivir for treatment of all hospitalized patients with suspected or confirmed cases and for outpatients at increased risk for complications of H1N1 infection.
As of September 2009, only 28 of 10,000 H1N1 isolates tested were resistant to oseltamivir (11 from the United States), and all were susceptible to zanamivir.
Although intravenous peramivir had not been formally FDA approved for the treatment of influenza during the 2009-2010 H1N1 pandemic, the FDA issued an emergency use authorization (EUA) for its use in hospitalized patients who had potentially life-threatening suspected or laboratory confirmed infection with H1N1. Under the EUA, treatment with IV peramivir was approved for patients who had not responded to either oral or inhaled antiviral therapy and/or drug delivery by a route other than IV that was not expected to be dependable or feasible.
Early administration of corticosteroids in patients with H1N1 who are admitted to the ICU has no apparent benefit.[75]
Avian influenza
Avian H5N1 influenza should be treated with oseltamivir, even after the 48-hour window, because a reduction in mortality of hospitalized persons with seasonal influenza or avian influenza A (H5N1) virus infection was reported even when oseltamivir treatment was initiated later. The optimal duration and dose is not clear, but the WHO recommends consideration of higher dosage (eg, 150 mg PO bid) and longer duration in severe infections.
Avian H5N1 influenza has exhibited resistance to oseltamivir (clade 1 and subclade 2.1 with H274Y and N294S mutations). These resistant strains maintained susceptibility to zanamivir. Some viruses circulating in birds (subclade 2.3.4) demonstrated reduced susceptibility to zanamivir but sensitivity to the adamantanes (amantadine/rimantadine). Thus, for resistant strains (especially subclades 2.2 and 2.3.4), consideration for combination therapy with neuraminidase inhibitor-adamantane or oseltamivir-ribavirin, or even triple therapy with neuraminidase inhibitor-adamantane-ribavirin, should be given.[53]
Respiratory Syncytial Virus Pneumonia
As with influenza, treatment of uncomplicated respiratory syncytial virus (RSV) infection is supportive in nature.
Ribavirin, a nucleoside analog of guanosine, is the only effective antiviral agent currently available for the treatment of RSV pneumonia.[55] Ribavirin acts by interfering with viral transcription; this drug is delivered as a small-particle aerosol. Data conflict regarding the efficacy of ribavirin therapy in RSV pneumonia. Overall, the preponderance of data suggests a benefit of ribavirin therapy in high-risk patients, such as hematopoietic stem cell transplant (HSCT) recipients.
Current recommendations are that ribavirin therapy should be considered only for severe illness and in high-risk patients for whom RSV infection is associated with high mortality, such as HSCT recipients.[54] In these hosts, high-dose, short-duration aerosolized ribavirin (60 mg/mL for 2 h given by mask tid) has been used.
RSV-specific intravenous immunoglobulin, such as palivizumab (Synagis), which is a monoclonal antibody directed against the RSV fusion (F) glycoprotein, has also been used with aerosolized and oral ribavirin in high-risk patients, such as HSCT recipients, because this combination has been shown to increase survival in this group[49] ; its use is endorsed in some guidelines, although not universally accepted or recommended.[76, 77]
Adenovirus Pneumonia
Cidofovir has demonstrated good in vitro activity against adenoviruses, including serotype 14. Cidofovir has shown some efficacy in treating adenovirus infection in immunocompromised patients, especially HSCT recipients.[78] The dose is 5 mg/kg/wk for 2 weeks, then every 2 weeks plus probenecid 1.25 g/m2 given 3 hours before cidofovir and 3 and 9 hours after each infusion. Alternate dosing is 1 mg/kg IV 3 times a week.
The in vitro activity of ribavirin against adenovirus, however, has been variable. For example, in one study, species C was susceptible to ribavirin, while other species were more variable.[79] Some anecdotal reports exist regarding improvement in some patients with HSCT and leukemia, although other studies have not shown any efficacy. Thus, routine use of ribavirin is not recommended.[80, 81, 82]
Parainfluenza Virus Pneumonia
Treatment is mainly supportive in nature. Ribavirin has shown in vitro activity against parainfluenza virus (PIV), and aerosolized and oral ribavirin were associated with reduction in PIV shedding and clinical improvement in immunocompromised patients; thus, in this latter, high-risk group, the use of ribavirin may be reasonable.[83]
Human Metapneumovirus Pneumonia
Although ribavirin has activity against human metapneumovirus (hMPV) similar to that which it has against RSV and although animal data have shown some promise, treatment data in humans are lacking, being confined to occasional case reports predominantly in the transplantation population.[84, 85]
Immunoglobulin preparations (intravenous immunoglobulin [IVIG]) also seem to contain sufficient neutralizing titers, but this has not been extensively studied for use in hMPV pneumonia either—again with only isolated case reports in patients with transplantation, usually in combination with ribavirin.[86]
Coronavirus Pneumonia
Protease inhibitors (eg, lopinavir/ritonavir) showed antiviral activity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection.[87] Interferon alfa and interferon beta have activity against SARS-CoV in vitro and in animal models. Limited human data seemed to show some beneficial effect.[88]
Ribavirin is not active against SARS-CoV in vitro, and studies have not shown clinical efficacy. Therefore, this medication is not recommended for this infection.[88]
Varicella-Zoster Virus Pneumonia
Treatment of varicella pneumonia includes respiratory isolation until skin lesions heal, supportive care, administration of antiviral agents, and active and passive immunization. For treatment of documented varicella pneumonia in patients who are immunocompromised, acyclovir (10 mg/kg IV q8h for 7 d) has been shown to be effective.
For pregnant women in the third trimester, acyclovir at 10 mg/kg IV every 8 hours for 5 days should be given, and consideration should be given for varicella-zoster immune globulin (VZIG) therapy.
Measles Pneumonia
Treatment of measles pneumonia generally is supportive in nature. Children infected with HIV and adults who are immunosuppressed with measles pneumonia have been treated successfully with intravenous (20-35 mg/kg/d for 7 d) and aerosolized ribavirin, similar to the therapy for severe infections with RSV.[89]
Cytomegalovirus Pneumonia
The primary treatment for acute cytomegalovirus (CMV) pneumonia in the immunocompromised patient (both HSCT and solid organ transplant [SOT] recipients) is ganciclovir (5 mg/kg IV 12h for 14-21 d, followed by valganciclovir 900 mg PO qd for suppression). Ganciclovir prevents viral DNA replication by inhibiting the enzyme DNA polymerase.
High-dose intravenous immunoglobulin (CMV immunoglobulin or IVIG) has been used successfully in conjunction with ganciclovir for the treatment of CMV pneumonia, decreasing the mortality rate to 0-47%. Combination therapy is based on the premise that lung injury is not solely due to direct damage by the virus but is a result of virally induced immunological reaction. In lung transplant recipients, ganciclovir with CMV immunoglobulin or IVIG has been associated with increased survival.[90]
Foscarnet sodium, an inhibitor of viral DNA polymerase and reverse transcriptase, is an alternative drug for use in ganciclovir-resistant CMV pneumonia. The combination of foscarnet with ganciclovir may provide antiviral synergy, but it requires careful monitoring.[91]
Cidofovir represents a third option, but scant data exist regarding its use in CMV pneumonia.
Herpes Simplex Virus Pneumonia
Acyclovir inhibits viral DNA synthesis by competitively binding to viral DNA polymerase. Intravenous acyclovir (250 mg/m2 q8h) currently is the treatment of choice for herpes simplex virus (HSV) pneumonia. Because a significant proportion of patients may have concomitant bacterial pneumonia, empirical broad-spectrum antibiotic therapy that includes an antistaphylococcal drug should be instituted in patients with progressive HSV pneumonia who are unresponsive to antiviral therapy.
Hantavirus Pneumonia
The treatment of hantavirus pulmonary syndrome (HPS) is supportive in nature and includes correction hypoxemia, lactic acidosis, and hypotension. Mechanical ventilation and optimal fluid management guided by hemodynamic monitoring are recommended, with avoidance of excessive administration of fluids and with use of cardiotonic drugs to counter the hemodynamic profile of decreased cardiac output and increased systemic vascular resistance.
Although intravenous ribavirin has been associated with some success in the treatment of some Bunyaviridae viruses, such as Hantaan virus (hemorrhagic fever with renal syndrome), Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus, it has failed to show any efficacy in HPS, perhaps because death typically occurred within 24-48 hours of hospitalization.[66]
Prevention
Influenza
Annual fall vaccination of high-risk populations and healthcare workers is the most effective measure for decreasing morbidity and mortality from influenza.[77] Each year's influenza vaccine contains the 3 virus strains (usually 2 type A strains and 1 type B strain) considered most likely to cause outbreaks based on epidemiologic surveillance; the 2010-2011 will also protect against H1N1 influenza.
In the United States, specific recommendations for vaccination against influenza are issued each year by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).[92]
The effectiveness of the vaccine depends on the age and general health status of the recipient and the antigenic similarity to the virus causing outbreaks that year. When the vaccine matches the prevalent influenza virus strain, the efficacy of the vaccine in healthy adults is reported to be in the range of 70-90%.
The effectiveness of widespread vaccination in elderly persons has been called into question. A recent meta-analysis of the efficacy, effectiveness, and safety of the influenza vaccine in patients older than 65 years found that vaccination is of benefit to residents of long-term care facilities but is of modest value in the community.[93] However, the Centers for Disease Control and Prevention (CDC) still recommend immunization of all elderly patients.[92]
The CDC has recommended chemoprophylaxis in the following situations:
- Close contacts of patients who are at high risk for complications of influenza
- Healthcare personnel, public health workers, and first responders who have had recognized and unprotected close contact exposure to a person with influenza during the person's infectious period (up to 7 d after onset of illness).
Chemoprophylaxis should be considered when outbreaks occur in nursing homes. Everyone in the institution, including the unvaccinated staff and other coworkers, should receive prophylactic therapy for at least 2 weeks during the outbreak.
The CDC issues updated interim guidance on antiviral treatment and prophylaxis of seasonal influenza, based on resistance patterns of the circulating viral strains.
Local influenza surveillance data and laboratory testing can also assist the physician regarding the antiviral agent choice.
Vaccines for avian H5N1 influenza are currently being developed and studied, and vaccinations have been performed in avian livestock (via whole-virus inactivated vaccine, recombinant fowlpox vaccine, and recombinant Newcastle disease vaccine.)
Respiratory syncytial virus
Respiratory syncytial virus (RSV) immunoglobulin is a pooled product containing immunoglobulin G antibodies against RSV. When administered intravenously to patients at high risk, fewer episodes of severe pneumonia requiring hospitalization have occurred.
An alternative to RSV immunoglobulin is palivizumab (Synagis), which is an intramuscularly administered humanized monoclonal antibody preparation. Prophylaxis with this agent results in a 55% reduction in hospitalization secondary to RSV infection in high-risk pediatric patients.
Vaccines are under development, including subunit vaccines directed against 2 major surface glycoproteins (F, G proteins), a polypeptide vaccine (BBG2Na), and live-attenuated vaccines, the latter of which have been promising in adults.
Adenovirus
An oral live vaccine was available against serotypes 4 and 7, taking advantage of the fact that exposure of these strains to the gastrointestinal tract does not result in illness. This vaccine was used primarily in military recruit populations, with excellent results, but it has not been available since 1999; recrudescence of adenovirus type 3, 4, and 7 has occurred in the military.
Other live and inactivated virus vaccines have been hampered by their oncogenicity in animal models. Vaccines against the capsid (and free of DNA) are currently being studied.
Parainfluenza virus
No vaccine is available, but live, attenuated, intranasally administered parainfluenza type 3 vaccines were under development.
Human metapneumovirus
No vaccine is available, although a live-attenuated bovine parainfluenza virus type 3 vaccine with human metapneumovirus F gene was being studied.[94]
Varicella-zoster virus
A live attenuated varicella vaccine is recommended for patients who did not have varicella infection by age 13 years and for anyone who is susceptible to varicella-zoster virus (VZV) (VZV antibody negative). The vaccine should not be given to pregnant women. Children are now routinely immunized before age 12-18 months.
Intramuscular administration of varicella-zoster immunoglobulin (125 U/10 kg to 625 units maximum) is indicated as passive immunization of VZV-seronegative personnel at risk for complications within 96 hours of being exposed to VZV (eg, immunosuppressed hosts, such as those with HIV or with malignancies; those on long-term steroid therapy; pregnant patients; and neonates whose mothers acquire VZV within 5 days before, to 48 hours after, delivery).
Measles
The measles vaccine is a live attenuated virus vaccine (part of measles-mumps-rubella [MMR] vaccine) and should be given to everyone except pregnant women or persons who are severely immunocompromised; HIV-infected persons who are asymptomatic or only mildly symptomatic should be vaccinated.
Postexposure prophylaxis of patients who are immunocompromised with intravenous immune globulin is effective if administered within 6 days of exposure to infectious cases of measles.
Cytomegalovirus
Cytomegalovirus (CMV) infection is prevented in transplant patients by attempts to match the CMV seropositivity between the donor and the recipient and by careful administration of CMV-negative transfusions of blood and blood products.
Hematopoietic stem cell transplant (HSCT) recipients who are CMV-negative are given prophylactic ganciclovir before and after transplantation. Solid organ transplant (SOT) recipients who are CMV-negative and receiving their organ from CMV-positive donors typically receive ganciclovir for 3 months post transplantation.
Preemptive therapy (with ganciclovir) based on detection of CMV in bronchoalveolar lavage specimens, CMV pp65 antigenemia, and/or polymerase chain reaction (PCR) in blood after transplantation has been shown to significantly reduce the incidence of post-transplant CMV pneumonia.
Herpes simplex virus
Chemoprophylaxis of high-risk seropositive patients during induction of immunosuppression for transplantation is recommended.
Acyclovir is routinely prescribed at maintenance doses for the first month after transplantation.
Hantavirus
No vaccine is available or in development. The only means of deterrence is by avoiding rodent contact and/or inhalation/aerosolization of areas of possible rodent excreta. If contact is unavoidable (ie, need to sweep dirty areas where rodents live), use of a respiratory mask is prudent.
Hematopoietic cell transplantation recipients
An international committee has produced guidelines for preventing infectious complications among HCT recipients. These guidelines include recommendations on use of antivirals for prevention or preemptive treatment of specific infections, as well as recommendations on vaccines.[95]
Complications
Most viral pneumonias in immunocompetent hosts resolve with few sequelae. However, respiratory failure may develop secondary to superimposed bacterial infection.
Secondary bacterial infections are common. Common organisms are Streptococcus pneumoniae, Staphylococcus aureus,Streptococcus pyogenes (group A Streptococcus), and Haemophilus influenzae.
Late sequelae of viral pneumonias include bronchitis and bronchiolitis, especially following infection with RSV and influenza viruses.
Adenovirus serotypes 2, 3, 7, and 21 have been the cause of serious chronic morbidity after acute respiratory illness, including irreversible atelectasis, bronchiectasis, bronchiolitis obliterans, and unilateral hyperlucent lung. An estimated 14-60% of these children will suffer some degree of permanent lung damage. Serious sequelae occurred in patients who survive severe infection with adenovirus 14.
A retrospective cohort study of 100 children with RSV revealed a 79% complication rate. Nearly 24% were considered serious, and 16% of children required mechanical ventilation. The authors concluded that RSV infections in children considerably lengthen their hospital stay and medical costs. In fact, hospital costs approach $1 billion annually in the United States. In addition, 20% of all patients are rehospitalized, and more than 40% develop asthma.
Complications of RSV pneumonia in children are a considerable burden on hospital costs. About 60% of the complications are respiratory and consist of respiratory failure, apnea, stridor, hemoptysis, infiltrates and/or atelectasis, hyperinflation, pneumothorax, or pleural effusions. About 15% of radiographs are described as normal in children with complications. Prematurity and congenital diseases are risk factors for complications.
Viral (mainly PIV) or bacterial (especially S pneumoniae) superinfections, tuberculosis reactivation, and subsequent bronchiectasis are complications of measles pneumonia.
Temporary decreases in the forced expiratory volume in 1 second (FEV1) and/or forced vital capacity (FVC) or a permanent decrease in the lung transfer factor for carbon monoxide (TLCO) are reported in patients with VZV pneumonia. One case of VZV pneumonia complicated by a bacterial lung abscess in a child is reported.
Consultations
Patients suspected of having viral pneumonia may benefit from consultation with pulmonary and infectious diseases specialists.
Korppi M, Don M, Valent F, Canciani M. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Paediatr. Jul 2008;97(7):943-7. [Medline].
Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. Jan 2008;63(1):42-8. [Medline].
Marcos MA, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther. 2006;Vol. 11:351-359.
Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis. Aug 1 2005;41(3):345-51. [Medline].
Levy MM, Baylor MS, Bernard GR, Fowler R, Franks TJ, Hayden FG, et al. Clinical issues and research in respiratory failure from severe acute respiratory syndrome. Am J Respir Crit Care Med. Mar 1 2005;171(5):518-26. [Medline].
Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. Sep 15 2003;168(6):633-9. [Medline].
Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis. Feb 15 2006;42(4):518-24. [Medline].
Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. Feb 28 1985;312(9):529-33. [Medline].
Metzgar D, Osuna M, Kajon AE, Hawksworth AW, Irvine M, Russell KL. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis. Nov 15 2007;196(10):1465-73. [Medline].
Louie JK, Kajon AE, Holodniy M, Guardia-LaBar L, Lee B, Petru AM, et al. Severe pneumonia due to adenovirus serotype 14: a new respiratory threat?. Clin Infect Dis. Feb 1 2008;46(3):421-5. [Medline].
Tate JE, Bunning ML, Lott L, Lu X, Su J, Metzgar D, et al. Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. J Infect Dis. May 15 2009;199(10):1419-26. [Medline].
Lewis PF, Schmidt MA, Lu X, Erdman DD, Campbell M, Thomas A, et al. A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. J Infect Dis. May 15 2009;199(10):1427-34. [Medline].
Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. Nov 1996;23(5):1033-7. [Medline].
van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. Jun 2001;7(6):719-24. [Medline].
Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. Mar 1 2003;187(5):785-90. [Medline].
Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. Nov 1 2002;186(9):1330-4. [Medline].
Cane PA, van den Hoogen BG, Chakrabarti S, Fegan CD, Osterhaus AD. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. Feb 2003;31(4):309-10. [Medline].
Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. Aug 2010;48(8):2940-7. [Medline]. [Full Text].
Lau SK, Woo PC, Yip CC, Tse H, Tsoi HW, Cheng VC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. Jun 2006;44(6):2063-71. [Medline]. [Full Text].
Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med. Apr 7 1994;330(14):949-55. [Medline].
Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med. Jun 1994;149(6):1710-3. [Medline].
Centers for Disease Control and Prevention. Hantavirus Pulmonary Syndrome (HPS) Cases, by State. Available at http://www.cdc.gov/ncidod/diseases/hanta/hps/noframes/epislides/episls.htm. Accessed August 24, 2010.
World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. Available at http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_08_12/en/index.html. Accessed August 24, 2010.
Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis. Nov 2004;4(11):663-71. [Medline].
Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care. Mar 2 2011;15(2):R80. [Medline].
Abughali N, Khiyami A, Birnkrant DJ, Kumar ML. Severe respiratory syncytial virus pneumonia associated with primary Epstein-Barr virus infection. Pediatr Pulmonol. May 2002;33(5):395-8. [Medline].
Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. Dec 2008;134(6):1141-8. [Medline].
Whitney CG, Harper SA. Lower respiratory tract infections: prevention using vaccines. Infect Dis Clin North Am. Dec 2004;18(4):899-917. [Medline].
Singh AM, Moore PE, Gern JE, Lemanske RF Jr, Hartert TV. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. Am J Respir Crit Care Med. Jan 15 2007;175(2):108-19. [Medline].
HILLEMAN MR. Epidemiology of adenovirus respiratory infections in military recruit populations. Ann N Y Acad Sci. Apr 19 1957;67(8):262-72. [Medline].
Anderson DJ, Jordan MC. Viral pneumonia in recipients of solid organ transplants. Semin Respir Infect. Mar 1990;5(1):38-49. [Medline].
Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. Jun 1992;165(6):987-93. [Medline].
Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. Jul 1 2004;170(1):22-48. [Medline].
Barton TD, Blumberg EA. Viral pneumonias other than cytomegalovirus in transplant recipients. Clin Chest Med. Dec 2005;26(4):707-20, viii. [Medline].
Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis. Nov-Dec 1982;4(6):1119-32. [Medline].
Maravi-Poma E, Martin-Loeches I, Regidor E, et al. Severe 2009 A/H1N1v influenza in pregnant women in Spain. Crit Care Med. May 2011;39(5):945-951. [Medline].
Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. Aug 13 2009;361(7):674-9. [Medline].
Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. Sep 15 2004;292(11):1333-40. [Medline].
Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep. Jul 17 2009;58(27):749-52. [Medline].
Centers for Disease Control and Prevention. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - April 10, 2010. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm. Accessed August 24, 2010.
World Health Organization. Pandemic (H1N1) 2009 - update 89. Available at http://www.who.int/csr/don/2010_02_26/en/index.html. Accessed March 3, 2010.
Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. Jul 2000;13(3):371-84. [Medline]. [Full Text].
Pelletier G, Déry P, Abed Y, Boivin G. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis. Sep 2002;8(9):976-8. [Medline]. [Full Text].
Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. Mar 7 2006;144(5):344-9. [Medline].
Tu CC, Chen LK, Lee YS, Ko CF, Chen CM, Yang HH, et al. An outbreak of human metapneumovirus infection in hospitalized psychiatric adult patients in Taiwan. Scand J Infect Dis. 2009;41(5):363-7. [Medline].
Engelhardt SJ, Halsey NA, Eddins DL, Hinman AR. Measles mortality in the United States 1971-1975. Am J Public Health. Nov 1980;70(11):1166-9. [Medline]. [Full Text].
World Health Organization. Reported measles cases and incidence rates by WHO Member States, 2009, 2010, as of Reported measles cases and incidence rates by WHO Member States, 2009, 2010, as of 13 August 2010. Available at http://www.who.int/immunization.../diseases/measlesreportedcasesbycountry.pdf. Accessed 13 August 2010.
US Centers for Disease Control and Prevention. Epidemiologic notes and reports: measles in HIV-infected children, United States. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00000002.htm. Accessed October 19, 2010.
Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med. Dec 2005;26(4):691-705, viii. [Medline].
Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med. Dec 1982;97(6):813-20. [Medline].
Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med. Mar 2009;53(3):358-65. [Medline].
Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract. Feb 1998;15(1):16-22. [Medline].
Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis. Jul 15 2009;49(2):279-90. [Medline].
Dowell SF, Anderson LJ, Gary HE Jr, Erdman DD, Plouffe JF, File TM Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. Sep 1996;174(3):456-62. [Medline].
Wald TG, Miller BA, Shult P, Drinka P, Langer L, Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons?. J Am Geriatr Soc. Feb 1995;43(2):170-4. [Medline].
WEBER DM, PELLECCHIA JA. VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN. JAMA. May 10 1965;192:572-3. [Medline].
Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med. Aug 2008;102(8):1109-16. [Medline].
Bonzel L, Tenenbaum T, Schroten H, Schildgen O, Schweitzer-Krantz S, Adams O. Frequent detection of viral coinfection in children hospitalized with acute respiratory tract infection using a real-time polymerase chain reaction. Pediatr Infect Dis J. Jul 2008;27(7):589-94. [Medline].
Falsey AR, McCann RM, Hall WJ, Criddle MM. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. J Am Geriatr Soc. Jan 1996;44(1):71-3. [Medline].
Osiowy C. Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J Clin Microbiol. Nov 1998;36(11):3149-54. [Medline]. [Full Text].
Luminex Corporation. Luminex Respiratory Viral Panel. Available at http://www.luminexcorp.com/rvp/overview.html.. Accessed August 28, 2009.
Pettila V, Webb SA, Bailey M, et al. Acute kidney injury in patients with influenza A (H1N1) 2009. Intensive Care Med. May 2011;37(5):763-7. [Medline].
Nin N, Lorente JA, Soto L, et al. Acute kidney injury in critically ill patients with 2009 influenza A (H1N1) viral pneumonia: an observational study. Intensive Care Med. May 2011;37(5):768-74. [Medline].
Erard V, Huang ML, Ferrenberg J, Nguy L, Stevens-Ayers TL, Hackman RC, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis. Oct 15 2007;45(8):958-65. [Medline].
Centers for Disease Control and Prevention. Acute respiratory disease associated with adenovirus serotype 14--four states, 2006-2007. MMWR Morb Mortal Wkly Rep. Nov 16 2007;56(45):1181-4. [Medline].
Kanne JP, Godwin JD, Franquet T, Escuissato DL, Müller NL. Viral pneumonia after hematopoietic stem cell transplantation: high-resolution CT findings. J Thorac Imaging. Aug 2007;22(3):292-9. [Medline].
Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis. May 1 2002;34(9):1224-31. [Medline].
Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. Sep 25 1997;337(13):874-80. [Medline].
Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. Oct 6 1999;282(13):1240-6. [Medline].
Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. Oct 28 1999;341(18):1336-43. [Medline].
Hirji Z, O'Grady S, Bonham J, Mak M, Takata-Shewchuk J, Hawkins K, et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population. Can Commun Dis Rep. Feb 1 2001;27(3):21-4. [Medline].
Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. Aug 1999;180(2):254-61. [Medline].
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. Feb 23 2000;283(8):1016-24. [Medline].
Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. Nov 15 2010;51(10):1167-75. [Medline].
Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. Feb 2011;37(2):272-83. [Medline].
Moscona A. Management of respiratory syncytial virus infections in the immunocompromised child. Pediatr Infect Dis J. Mar 2000;19(3):253-4. [Medline].
Swedish Consensus Group. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis. 2001;33(5):323-8. [Medline].
Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. May 1 2001;32(9):1290-7. [Medline].
Morfin F, Dupuis-Girod S, Frobert E, Mundweiler S, Carrington D, Sedlacek P, et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther. 2009;14(1):55-61. [Medline].
Kapelushnik J, Or R, Delukina M, Nagler A, Livni N, Engelhard D. Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. J Pediatr Gastroenterol Nutr. Jul 1995;21(1):110-2. [Medline].
McCarthy AJ, Bergin M, De Silva LM, Stevens M. Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. Nov 1995;14(11):1003-4. [Medline].
Adenovirus. Am J Transplant. Nov 2004;4 Suppl 10:101-4. [Medline].
Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. Oct 2001;28(8):759-63. [Medline].
Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. Apr 2008;41(8):707-8. [Medline].
Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. Aug 2007;26(8):862-4. [Medline].
Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. Jun 2009;145(5):667-9. [Medline].
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. Mar 2004;59(3):252-6. [Medline]. [Full Text].
Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. Sep 2004;31(1):69-75. [Medline].
Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. Sep 1994;19(3):454-62. [Medline].
Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant. Aug 2004;4(8):1219-26. [Medline].
Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Moro F, et al. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct). Bone Marrow Transplant. Nov 1996;18 Suppl 2:110-4. [Medline].
Centers for Disease Control and Prevention. Seasonal Influenza (Flu). Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at http://www.cdc.gov/flu/professionals/acip/. Accessed August 22, 2010.
van der Hoek L. Human coronaviruses: what do they cause?. Antivir Ther. 2007;12(4 Pt B):651-8. [Medline].
Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. Oct 2003;77(20):10819-28. [Medline]. [Full Text].
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. Oct 2009;15(10):1143-238. [Medline]. [Full Text].
de Jong MD, Hien TT. Avian influenza A (H5N1). J Clin Virol. Jan 2006;35(1):2-13. [Medline].
Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest. Jan 2006;129(1):156-68. [Medline].
| Virus | Viral Culture | Cytologic Evaluation | Rapid Antigen Detection | Gene Amplification |
| Influenza virus | HA*, SV† | IF‡, ELISA§ | RT-PCR# | |
| Adenovirus | CE, SV | Intranuclear inclusions | IF, ELISA | RT-PCR |
| Paramyxoviruses | ||||
| Respiratory syncytial virus | CE, SV | Eosinophilic cytoplasmic inclusions | IF, ELISA | RT-PCR |
| Parainfluenza virus | HA, SV | Eosinophilic intranuclear inclusions | IF, ELISA | RT-PCR |
| Measles virus | HA | |||
| Herpes viruses | ||||
| Herpes simplex virus | CE, SV | Cytoplasmic inclusions | IF, ELISA | PCR |
| Varicella-zoster virus | CE | Cytoplasmic inclusions | IF | RT-PCR |
| Cytomegalovirus | CE, SV | "Owl's eye" cells | IF, ELISA | RT-PCR |
| Hantavirus | Antibodies against FCV** | FVC RNA by RT-PCR | ||
| * HA - Hemaglutination † SV - Shell viral culture ‡ IF - Immunofluorescence § ELISA - Enzyme-linked immunosorbent assay CE - Cytopathogenic effects # RT-PCR - Reverse transcriptase polymerase chain reaction ** FCV - Four corners virus | ||||
| Virus | Treatment | Prevention |
| Influenza virus | Amantadine Rimantadine | Influenza vaccine Chemoprophylaxis with: Amantadine Rimantadine Zanamivir Oseltamivir |
| Respiratory syncytial virus | Ribavirin | RSV immunoglobulin Palivizumab |
| Parainfluenza virus | Ribavirin | |
| Herpes simplex virus | Acyclovir | |
| Varicella-zoster virus | Acyclovir | Varicella-zoster immunoglobulin |
| Adenovirus | Ribavirin | |
| Measles virus | Ribavirin | Intravenous immunoglobulin |
| Cytomegalovirus | Ganciclovir Foscarnet | Intravenous immunoglobulin |
| Amantadine (Symmetrel) | Rimantadine (Flumadine) | Zanamivir (Relenza) | Oseltamivir (Tamiflu) | |
| Mechanism of action | M2 ion channel blockade inhibits HA* cleavage beta block RNA encoding, which reduces early viral replication. | Viral NA† inhibition prevents sialic acid cleavage from HA beta virus gets trapped inside cells, and epithelial spread is blocked. | ||
| Spectrum | Influenza A only | Influenza A only | Influenza A and B | Influenza A and B |
| Oral bioavailability | Good | Good | Poor | Good |
| Protein binding, % | 67 | 40 | None | Minimal |
| Half-life, h | 12-18 | 24-36 | 2.5-5 | 1-3 |
| Excretion | Renal (not removed by hemodialysis) | Renal and gastrointestinal | Renal | |
| Drug interaction | Synergistic CNS toxicity with antihistamines, anticholinergics, CNS stimulants | Beta Plasma level: ASA§, acetaminophen | None | None |
| Renal clearance | TMP-SMZ¶, triamterene, hydrochlorothiazide, quinine sulfate, quinidine | Cimetidine | None | None |
| * HA - Hemagglutinin † NA - Neuraminidase § ASA - Acetylsalicylic acid ¶ TMP-SMZ - Trimethoprim and sulfamethoxazole | ||||

